To identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines.

Ended Definitive Contract Awarded Last action

Contract number
75N93019C00043
Awardee
Awarding agency
Obligated
$10,725,896

Award facts

Opportunity
Contract value 100% obligated
$10,725,896.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 12 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Portland, OR 97239, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00015 · Vaccine adjuvant discovery program $0
Other Administrative Action P00014 $0
Other Administrative Action P00013 $0
Other Administrative Action P00012 $0
Exercise an Option P00011 $2,104,354
Other Administrative Action P00010 $0
Exercise an Option P00009 $2,267,043
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Exercise an Option P00004 $2,090,420
Other Administrative Action P00003 $0
Exercise an Option P00002 · Exercise OPT 1. To identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. $2,202,887
Other Administrative Action P00001 $2,061,192
Original award $0
Show all 16

About this award

Written by GovTribe AI ·

This is a $10,725,896 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Oregon Health & Science University (OHSU). The contract is for the Vaccine Adjuvant Discovery Program, which aims to identify novel adjuvant candidates that can enhance the efficacy of human vaccines. The contract is a definitive, cost-no-fee contract with a performance period ending on March 31, 2026. No set-aside was used. The work includes testing adjuvant candidates with experimental or FDA-approved vaccines in animal models to determine potential efficacy against human pathogens. OHSU is the prime contractor, with several academic institutions like Drexel University and the University of Washington serving as subcontractors on the development of novel STING pathway agonists as vaccine adjuvants.

Subawards

Subcontractor Amount Awarded
Drexel University TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. Development of Novel STING Pathway Agonists as Vaccine… $11
Inimmune Corp TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. Development of Novel STING Pathway Agonists as Vaccine… $466,139

Quick answers

Who was awarded contract 75N93019C00043?

75N93019C00043 was awarded to Oregon Health & Science University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 12, 2019.

How much is contract 75N93019C00043 worth?

The government has obligated $10,725,896 on 75N93019C00043.

Was contract 75N93019C00043 competed?

The extent of competition for 75N93019C00043 was full and open competition. The government received 12 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login